Drugs / Duloxetine
Duloxetine
also known as
Cymbalta · duloxetine hydrochloride · Duloxetine HCl · Ariclaim · Cymbalta (duloxetine) · Cymbatex · DLX · Drizalma sprinkle · +19 more
Small molecule targets CYP2D6, SLC6A2, SLC6A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | DRIZALMA SPRINKLE | — | 2021-07-23 | fda.gov ↗ |
| Label expansions (6) | US (FDA) | CYMBALTA | — | 2007-02-23 – 2020-04-20 | fda.gov ↗ |
| Approved | EU (EMA) | Yentreve | — | 2004-08-11 | europa.eu ↗ |
| Approved | US (FDA) | CYMBALTA | — | 2004-08-03 | fda.gov ↗ |
Trials 249 · started per year
today
US approved 2004
EU approved 2004
6
8
10
12
19
21
19
16
20
12
5
6
7
7
6
8
5
7
4
9
16
4
6
8
2
4
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05292066 | Oct → Dec 2022 | neuropathy, painful | Aga Khan University | Unknown | No outcome recorded |
| Phase 0 | NCT03623711 | Aug 2018 → Dec 2022 | major depressive disorder | Yuqi Cheng | Unknown | No outcome recorded |
| Phase 0 | NCT00763178 | Feb 2007 → Apr 2009 | post-traumatic stress disorder | Yale University | Completed | No outcome recorded |
| Phase 115 trials | ||||||
| Phase 1 | NCT04836533 | Jan 2023 | depressive disorder | Queens College, The City University of New York | Withdrawn | No outcome recorded |
| Phase 1 | NCT05065671 | Feb 2022 → Sep 2025 | — | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 1 | NCT04751318 | Feb 2021 | — | Laboratorios Andromaco S.A. | Completed | No outcome recorded |
| Phase 1 | NCT04723238 | Jan → Feb 2021 | — | Laboratorios Andromaco S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03575403 | Sep 2018 → Mar 2023 | alcohol-related disorders | Craig Rush | Completed | No outcome recorded |
| Phase 1 | NCT02869035 | Aug 2016 → Jul 2019 | major depressive disorder | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 1 | NCT02700711 | Feb 2016 → Jun 2018 | substance-related disorder | University of Kentucky | Completed | No outcome recorded |
| Phase 1 | NCT02174822 | Jan → Mar 2014 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00990067 | Nov 2009 → May 2010 | mood disorder, substance-related disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT00933452 | Jul → Nov 2009 | — | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase 1 | NCT02291367 | May 2008 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT02291341 | May 2008 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT00414323 | Nov 2006 → May 2007 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00387413 | Oct 2006 → May 2007 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02232542 | Jun → Aug 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05949229 | Aug 2023 → Aug 2026 overdue | delirium | Amira Hassan Ahmed Ali | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05814640 | Feb 2023 → Dec 2026 expected | major depressive disorder, splenic sequestration | First Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 224 trials | ||||||
| Phase 2 | NCT07431606 | May 2026 → Mar 2027 expected | inflammatory bowel disease | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 2 | NCT06614322 | Jan 2026 → Jun 2028 expected | chemotherapy-induced neuropathy, diabetic polyneuropathy, neuropathy, painful | University of Rochester | Recruiting | No outcome recorded |
| Phase 2 | NCT06551051 | Aug 2024 → Dec 2025 overdue | cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05611749 | May 2023 → Mar 2024 | chronic pain syndrome, opiate dependence | Scripps Health | Terminated | No outcome recorded |
| Phase 2 | NCT05110144 | Nov 2021 → Dec 2026 expected | — | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT05120934 | Nov 2021 → Oct 2026 expected | interstitial lung disease | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT04111627 | Oct 2021 → Aug 2025 | depressive disorder, osteoarthritis, knee | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 2 | NCT04970121 | Aug 2021 → Jul 2025 overdue | cancer, chemotherapy-induced neuropathy | Yan Yang, MD, Ph.D | Recruiting | No outcome recorded |
| Phase 2 | NCT04437485 | Oct 2020 → Aug 2022 | dysthymic disorder, major depressive disorder, prediabetes syndrome, type 2 diabetes mellitus | Indiana University | Completed | No outcome recorded |
| Phase 2 | NCT04560673 | Jul 2020 → Dec 2026 expected | cancer, chemotherapy-induced neuropathy, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03315533 | Jan 2018 → Mar 2019 | musculoskeletal system disorder | Rhode Island Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03038867 | Dec 2016 → Aug 2018 | depressive disorder, male infertility | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT02857244 | Nov 2016 → Nov 2017 | Parkinson disease | University of Chicago | Withdrawn | No outcome recorded |
| Phase 2 | NCT02458690 | Jul 2015 → Aug 2019 | coronary artery disorder, dysthymic disorder, major depressive disorder, stroke disorder | Indiana University | Completed | No outcome recorded |
| Phase 2 | NCT02307305 | Aug 2014 → Dec 2016 | neuropathy, painful | Hanyang University Seoul Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01912612 | Oct 2013 → Jun 2019 | — | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00929344 | Jul 2009 → Oct 2014 | alcohol dependence | The Scripps Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00863057 | May 2009 → Dec 2010 | HIV infectious disease, peripheral neuropathy | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT00837941 | Apr → Aug 2009 | diabetic polyneuropathy | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT00742573 | Aug 2008 → Jan 2014 | major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT00529789 | Aug 2007 → Sep 2008 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00475696 | Nov 2002 → Mar 2005 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00190606 | Jan 2002 → Apr 2006 | urinary system disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00190567 | Oct 2001 → Apr 2006 | female stress incontinence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT04747314 | Mar 2021 → Nov 2024 | anxiety, chronic pain syndrome | Ajay Wasan, MD, Msc | Completed | No outcome recorded |
| Phase 2/3 | NCT04137107 | Jun 2020 → Feb 2026 overdue | digestive system carcinoma | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00370656 | Feb 2007 → May 2009 | diabetes mellitus, peripheral neuropathy | University of Surrey | Completed | No outcome recorded |
| Phase 2/3 | NCT00457730 | Jan 2007 → Aug 2012 | multiple sclerosis | Brown, Theodore R., M.D., MPH | Completed | No outcome recorded |
| Phase 2/3 | NCT00375973 | Sep 2006 → Jun 2012 | myalgic encephalomeyelitis/chronic fatigue syndrome | University of Cincinnati | Completed | No outcome recorded |
| Phase 2/3 | NCT00215228 | Jul 2005 → Aug 2007 | major depressive disorder | Duke University | Completed | No outcome recorded |
| Phase 2/3 | NCT00136383 | Mar 2005 → Jun 2007 | depressive disorder | Duke University | Completed | No outcome recorded |
| Phase 380 trials | ||||||
| Phase 3 | NCT06407401 | Dec 2024 → Apr 2028 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, musculoskeletal system disorder | European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06606067 | Sep 2024 → Jul 2026 overdue | chronic pain syndrome | Parc de Salut Mar | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05677295 | Apr 2023 → Dec 2024 | female stress incontinence | Far Eastern Memorial Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03068247 | Nov 2021 → May 2023 | major depressive disorder | University of Utah | Withdrawn | No outcome recorded |
| Phase 3 | NCT04364997 | Jun 2020 → Sep 2021 | major depressive disorder | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04412876 | May 2020 | female stress incontinence | Far Eastern Memorial Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT03395353 | Jan 2018 → Jul 2020 | depressive disorder | Shionogi | Terminated | No outcome recorded |
| Phase 3 | NCT03315793 | Dec 2017 → Nov 2019 | depressive disorder | Shionogi | Completed | No outcome recorded |
| Phase 3 | NCT03249168 | Oct 2017 → Nov 2018 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT02335346 | Jan 2015 → Mar 2016 | osteoarthritis, knee | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT02248480 | Oct 2014 → Jun 2015 | osteoarthritis, knee | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01931475 | Sep 2013 → Mar 2015 | osteoarthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01914666 | Sep 2013 → Dec 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01598298 | May 2013 → Dec 2016 | breast cancer, musculoskeletal system disorder | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT01855919 | May 2013 → Jul 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01621191 | Jun 2012 → Feb 2014 | fibromyalgia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01552057 | Mar 2012 → Dec 2013 | fibromyalgia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01226511 | Jun 2011 → Feb 2013 | anxiety disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01504178 | May 2011 → Dec 2015 | Parkinson disease | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 3 | NCT01179672 | Apr 2011 → Aug 2013 | diabetic polyneuropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01237587 | Mar 2011 → May 2017 | fibromyalgia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01140906 | May 2010 → Sep 2011 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT01089556 | Mar 2010 → Nov 2011 | diabetic neuropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01018680 | Nov 2009 → Apr 2011 | osteoarthritis, knee | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00989157 | Sep 2009 → Oct 2012 | — | Neuropsychiatric Research Institute, Fargo, North Dakota | Completed | No outcome recorded |
| Phase 3 | NCT00945945 | Jul 2009 → May 2010 | osteoarthritis, knee | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00849901 | Mar 2009 → Mar 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00849693 | Mar 2009 → Feb 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00811252 | Jan 2009 → Feb 2010 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00803361 | Dec 2008 → Jan 2010 | generalized anxiety disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00755807 | Oct 2008 → Aug 2010 | multiple sclerosis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00767806 | Sep 2008 → Jul 2009 | chronic pain syndrome | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00489411 | Apr 2008 → Jan 2012 | cancer of unknown primary site, chemotherapy-induced toxicity, peripheral neuropathy | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00641719 | Mar 2008 → Mar 2010 | diabetic neuropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00635219 | Feb 2008 → Apr 2009 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00552175 | Nov 2007 → Mar 2009 | diabetic neuropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00433290 | Feb 2007 → May 2008 | osteoarthritis, knee | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00424593 | Jan → Dec 2007 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00552682 | Jan 2007 → Jul 2009 | HIV infectious disease, fibromyalgia | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00408993 | Dec 2006 → Feb 2008 | diabetic neuropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00408876 | Dec 2006 → Nov 2007 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00408421 | Nov 2006 → Oct 2007 | osteoarthritis, knee | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00366652 | Sep 2006 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00384033 | Sep 2006 → Sep 2007 | major depressive disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00321490 | Apr 2006 → May 2007 | major depressive disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00583193 | Dec 2005 → Jun 2008 | post-traumatic stress disorder | Canive, Jose M., M.D. | Unknown | No outcome recorded |
| Phase 3 | NCT00233025 | Sep 2005 → Jun 2007 | fibromyalgia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00125892 | Jul 2005 → Mar 2007 | fibromyalgia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00190866 | Jun 2005 → Jun 2007 | fibromyalgia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02232555 | May 2005 → May 2006 | major depressive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00191919 | May 2005 → May 2006 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00122837 | Apr 2005 → Jan 2007 | anxiety disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00105989 | Mar 2005 → Jan 2008 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00191594 | Mar 2005 → Aug 2006 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00122863 | Jan 2005 → Mar 2007 | anxiety disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00190853 | Jan 2005 → Sep 2006 | female stress incontinence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00122850 | Oct 2004 → Nov 2005 | anxiety disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00475969 | Aug 2004 → Jun 2005 | generalized anxiety disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00122824 | Jun 2004 → Sep 2005 | generalized anxiety disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00191685 | May 2004 → Sep 2005 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00489775 | Jan 2004 → Jun 2005 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00475397 | Dec 2003 → Oct 2004 | female stress incontinence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00073411 | Nov 2003 → May 2005 | depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00190814 | Sep 2003 → May 2006 | female stress incontinence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00190827 | Sep 2003 → May 2006 | female stress incontinence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00475358 | Apr 2003 → Feb 2005 | female stress incontinence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00062673 | Mar 2003 → Jul 2004 | depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00190996 | Jan 2003 → Jun 2006 | female stress incontinence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00042562 | Dec 2002 → Dec 2003 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00489073 | Nov 2002 → Dec 2003 | fibromyalgia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00058968 | Oct 2002 → Mar 2005 | diabetic polyneuropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00042575 | Jun → Aug 2002 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00036309 | May 2002 → Jul 2003 | depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00036335 | Mar 2002 → Jan 2003 | depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00191204 | Sep 2001 → May 2006 | female stress incontinence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00190619 | May 2001 → May 2006 | urinary bladder disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00191087 | Apr 2001 → May 2006 | female stress incontinence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00190632 | Mar 2001 → Apr 2006 | female stress incontinence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00190645 | Feb 2001 → May 2006 | female stress incontinence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 486 trials | ||||||
| Phase 4 | NCT05976347 | Jun 2025 → May 2027 expected | depressive disorder | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT06807866 | Mar 2025 → Dec 2026 expected | — | University of Miami | Recruiting | No outcome recorded |
| Phase 4 | NCT06423716 | Nov 2024 → Jul 2026 overdue | osteoarthritis, knee | Sunnybrook Health Sciences Centre | Recruiting | No outcome recorded |
| Phase 4 | NCT05851898 | Apr 2024 → Dec 2028 expected | osteoporosis | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT06232473 | Jan 2024 → Nov 2027 expected | — | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05851976 | Oct 2023 → May 2027 expected | — | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT04639011 | Oct 2022 → Dec 2023 | — | Boston Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT05086393 | Nov 2021 → Jun 2025 | neuropathy, painful | Rush University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04870957 | Jun 2021 → Oct 2024 | chronic pain syndrome | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT04782310 | Mar → Aug 2021 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04697693 | Mar → May 2021 | major depressive disorder, post-traumatic stress disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 4 | NCT04395001 | Feb 2021 → Jul 2024 | chronic pain syndrome | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT04388189 | Oct 2020 → May 2023 | major depressive disorder | Alto Neuroscience | Withdrawn | No outcome recorded |
| Phase 4 | NCT03729284 | Mar → Jun 2020 | — | Pfizer | Withdrawn | No outcome recorded |
| Phase 4 | NCT03794154 | Mar → Jun 2020 | — | Pfizer | Withdrawn | No outcome recorded |
| Phase 4 | NCT04246619 | Nov 2019 → Dec 2021 | diabetic polyneuropathy | KRKA | Terminated | No outcome recorded |
| Phase 4 | NCT04117893 | Oct 2019 → Jun 2021 | chronic pain syndrome, osteoarthritis, knee | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03792828 | Jan → Oct 2019 | osteoarthritis, knee | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03548454 | Sep 2018 → Dec 2023 | chronic pain syndrome | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT03271151 | Sep 2017 → Dec 2020 | arthropathy, chronic pain syndrome | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 4 | NCT02846701 | Nov 2016 → Jun 2017 | neuropathy, painful | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| Phase 4 | NCT02351440 | Apr 2016 → Aug 2017 | — | Northwestern University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02590874 | Jan 2016 → Jul 2017 | cognitive impairment with or without cerebellar ataxia, depressive disorder | University of North Texas Health Science Center | Completed | No outcome recorded |
| Phase 4 | NCT02711215 | May 2015 → Jan 2020 | major depressive disorder | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT02417935 | Apr 2015 → May 2017 | diabetic polyneuropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT02208778 | Dec 2014 → Jun 2016 | chronic pain syndrome, osteoarthritis | University of Nottingham | Completed | No outcome recorded |
| Phase 4 | NCT02260388 | Oct 2014 → Sep 2017 | idiopathic progressive polyneuropathy | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01973283 | Feb 2014 → Dec 2019 | dysthymic disorder, major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT02005601 | Nov 2013 → May 2015 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 4 | NCT01916824 | Aug 2013 → Dec 2015 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01796132 | Aug 2012 → Dec 2016 | depressive disorder, lactation disease | Centre Hospitalier Universitaire Vaudois | Unknown | No outcome recorded |
| Phase 4 | NCT01619566 | Jun 2012 → Jan 2015 | fibromyalgia | University of California, San Diego | Withdrawn | No outcome recorded |
| Phase 4 | NCT01558700 | Mar 2012 → Apr 2014 | osteoarthritis | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT01391221 | Jul 2011 → Aug 2013 | major depressive disorder | Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal | Unknown | No outcome recorded |
| Phase 4 | NCT01118780 | Oct 2010 → Jul 2012 | generalized anxiety disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01166048 | May 2010 → Jun 2014 | chronic pain syndrome | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01070329 | Mar 2010 → Mar 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01089621 | Mar → Aug 2010 | fibromyalgia | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 4 | NCT01078870 | Feb 2010 → Jan 2011 | schizophrenia | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01051466 | Jan 2010 → Mar 2013 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01000805 | Nov 2009 → Oct 2010 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00961298 | Sep 2009 → Dec 2011 | generalized anxiety disorder, irritable bowel syndrome | West Penn Allegheny Health System | Completed | No outcome recorded |
| Phase 4 | NCT00985504 | Sep 2009 → Dec 2010 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00965081 | Sep 2009 → Nov 2010 | fibromyalgia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00960986 | Aug 2009 → Feb 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01117857 | Aug 2009 → Jun 2011 | depressive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00889369 | May 2009 → Feb 2012 | major depressive disorder | Hamilton Health Sciences Corporation | Unknown | No outcome recorded |
| Phase 4 | NCT00844194 | Feb 2009 → Jun 2010 | diabetic polyneuropathy, major depressive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT01754493 | Dec 2008 → Dec 2014 | irritable bowel syndrome, major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00810069 | Nov 2008 → Feb 2010 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00673452 | Jun 2008 → Apr 2009 | fibromyalgia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00696774 | Jun 2008 → Jul 2009 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00666757 | May 2008 → Feb 2009 | depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00658931 | Apr 2008 → Apr 2010 | major depressive disorder | Jefferson Clinic, P.C. | Unknown | No outcome recorded |
| Phase 4 | NCT00532480 | Sep 2007 → Apr 2009 | major depressive disorder | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT00536471 | Sep 2007 → May 2008 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00443352 | Aug 2007 → Nov 2012 | migraine disorder | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 4 | NCT00696293 | May 2007 → Mar 2010 | major depressive disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00437125 | Mar 2007 → Jul 2009 | Parkinson disease, major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT02229825 | Feb 2007 → Aug 2008 | major depressive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00422162 | Feb 2007 → Aug 2008 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00517985 | Feb 2007 → Jun 2008 | major depressive disorder | University of Arizona | Completed | No outcome recorded |
| Phase 4 | NCT00406848 | Nov 2006 → Jul 2009 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00401258 | Nov 2006 → Feb 2008 | irritable bowel syndrome | Mclean Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00398632 | Nov 2006 → Apr 2009 | depressive disorder | Stanford University | Terminated | No outcome recorded |
| Phase 4 | NCT00607789 | Oct 2006 → Oct 2009 | binge eating disorder, depressive disorder | University of Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT00385671 | Sep 2006 → Aug 2009 | diabetic polyneuropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00438971 | Aug 2006 → Jan 2009 | panic disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00360724 | Aug 2006 → Dec 2011 | depressive disorder, dysthymic disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT01035073 | Apr 2006 → May 2009 | major depressive disorder, myofascial pain syndrome | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT00531895 | Apr 2006 → Mar 2007 | headache disorder, major depressive disorder | Kraepelin Psiquiatria Clinica | Completed | No outcome recorded |
| Phase 4 | NCT00322621 | Apr 2006 → Oct 2007 | diabetic neuropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01852383 | Jan 2006 → Sep 2010 | depressive disorder, dysthymic disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00266643 | Dec 2005 → Apr 2007 | diabetic polyneuropathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00464698 | Dec 2005 → Dec 2013 | obsessive-compulsive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00244296 | Oct 2005 → Jan 2007 | female stress incontinence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00224302 | Aug 2005 → Nov 2007 | psychotic disorder | Central Institute of Mental Health, Mannheim | Completed | No outcome recorded |
| Phase 4 | NCT00296699 | Mar 2005 → Jun 2007 | atypical depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00191061 | Oct 2004 → Jan 2006 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00118430 | Sep 2004 → Jul 2008 | depressive disorder | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT00609557 | Sep 2004 → Feb 2007 | osteoarthritis | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT00479726 | Aug 2004 → Jan 2005 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00191932 | Aug 2004 → Mar 2006 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00190905 | Feb 2004 → Jul 2005 | female stress incontinence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00071695 | Jul 2003 → May 2004 | depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00067912 | Apr 2003 → Mar 2004 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase not applicable31 trials | ||||||
| — | NCT07654179 | Jun 2026 → Jun 2027 expected | depressive disorder, obesity disorder | Riphah International University | Recruiting | No outcome recorded |
| — | NCT07421427 | Feb 2026 → Jan 2027 expected | chronic pain syndrome | Cairo University | Recruiting | No outcome recorded |
| — | NCT06711978 | Dec 2024 → May 2025 overdue | chemotherapy-induced neuropathy | Pusan National University Yangsan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06429605 | May → Dec 2024 | — | Erzincan Military Hospital | Completed | No outcome recorded |
| — | NCT05311774 | Apr 2022 → Oct 2025 | — | Assiut University | Completed | No outcome recorded |
| — | NCT04313335 | Mar 2021 → May 2023 | postherpetic neuralgia | Beijing Tiantan Hospital | Completed | No outcome recorded |
| — | NCT04732455 | Jan 2021 → Jun 2022 | breast cancer, chemotherapy-induced neuropathy | Gamal Mohamed Taha Abouelmagd | Completed | No outcome recorded |
| — | NCT04719585 | Jan 2021 → Dec 2022 | osteoarthritis, knee | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT04478526 | Apr 2020 → May 2021 | generalized anxiety disorder | Dr. Nazanin Alavi | Completed | No outcome recorded |
| — | NCT03880916 | Mar 2019 → Mar 2020 | osteoarthritis, knee | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT03560427 | Sep 2018 → Mar 2020 | — | Assiut University | Completed | No outcome recorded |
| — | NCT03549026 | Jan 2018 → Dec 2019 | — | Assiut University | Unknown | No outcome recorded |
| — | NCT03276689 | Oct 2017 → Dec 2020 | neuropathy, painful | Rambam Health Care Campus | Completed | No outcome recorded |
| — | NCT03148522 | Jun 2017 → Dec 2021 | — | Peking University | Unknown | No outcome recorded |
| — | NCT03054220 | Jul 2016 → Dec 2018 | — | Jules Desmeules | Completed | No outcome recorded |
| — | NCT02600247 | Nov 2015 → Nov 2016 | osteoarthritis | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT03121573 | Dec 2014 → Sep 2016 | major depressive disorder | Taichung Veterans General Hospital | Completed | No outcome recorded |
| — | NCT01650740 | Aug 2012 → Aug 2014 | major depressive disorder | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded |
| — | NCT01269866 | Dec 2010 → May 2012 | systemic lupus erythematosus | Dr. Jesus Gutierrez Stone | Completed | No outcome recorded |
| — | NCT01425827 | Nov 2010 → Jun 2011 | — | University of Alexandria | Completed | No outcome recorded |
| — | NCT01363284 | Jun 2010 → Aug 2012 | diabetes mellitus, neuropathy, painful | Rambam Health Care Campus | Completed | No outcome recorded |
| — | NCT01127490 | May 2010 → Sep 2015 | fibromyalgia | Albany Medical College | Completed | No outcome recorded |
| — | NCT00981149 | May 2009 → Nov 2011 | temporomandibular joint disorder | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT01028352 | Oct 2008 → Nov 2010 | breast cancer | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| — | NCT00617045 | Jul 2007 → Dec 2012 | major depressive disorder, postpartum depression | Yale University | Withdrawn | No outcome recorded |
| — | NCT00491348 | Apr 2007 → Nov 2008 | anxiety | National Taiwan University Hospital | Terminated | No outcome recorded |
| — | NCT00425230 | Jan → Jun 2007 | — | Baylor College of Medicine | Terminated | No outcome recorded |
| — | NCT00388414 | Sep 2006 → Jan 2010 | — | Stanford University | Completed | No outcome recorded |
| — | NCT00933439 | Feb 2005 → Sep 2007 | major depressive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT00185575 | Sep 2004 → Apr 2006 | depressive disorder | Stanford University | Completed | No outcome recorded |
| — | NCT00399022 | — | obsessive-compulsive disorder | Sheba Medical Center | Withdrawn | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00071708 | — | diabetic polyneuropathy, fibromyalgia, generalized anxiety disorder, major depressive disorder | Eli Lilly and Company | Approved for marketing | No outcome recorded |
Also used as a comparator or background therapy in 138 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07400471 Comparator | Feb 2026 → Mar 2027 expected | — | Chattogram International Dental College | Recruiting | No outcome recorded |
| Phase 0 | NCT05508516 Comparator | Sep 2022 → Oct 2024 | fibromyalgia | China-Japan Friendship Hospital | Completed | No outcome recorded |
| Phase 0 | NCT01688570 Comparator | Aug 2011 → May 2015 | stroke disorder | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT06965569 Background | Apr → Dec 2025 | — | Alar Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04862845 Comparator | Jul 2021 → Dec 2025 | — | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT04178993 Comparator | Sep 2019 → May 2021 | methamphetamine dependence | Craig Rush | Completed | No outcome recorded |
| Phase 1 | NCT00533026 Comparator | Jul → Oct 2007 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03110172 Comparator | Jan → Jun 2017 | osteoarthritis, knee | Dalian Municipal Central Hospital | Unknown | No outcome recorded |
| Phase 228 trials | ||||||
| Phase 2 | NCT07649291 Comparator | Mar 2027 → Sep 2031 expected | depressive disorder, osteoarthritis, knee | VA Office of Research and Development | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06842992 Comparator | Dec 2024 → Jul 2025 | major depressive disorder | Jiangsu Nhwa Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06259526 Comparator | Dec 2023 → Oct 2024 | depressive disorder | Tasly Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT06091553 Comparator | Oct 2023 → Sep 2024 | peripheral neuropathy | Beni-Suef University | Unknown | No outcome recorded |
| Phase 2 | NCT05486026 Comparator | Aug → Dec 2022 | osteoarthritis, knee | Hawler Medical University | Completed | No outcome recorded |
| Phase 2 | NCT05115123 Comparator | Mar → Apr 2022 | neuropathy, painful | Mansoura University | Completed | No outcome recorded |
| Phase 2 | NCT05018013 Comparator | Aug 2021 → Aug 2022 | major depressive disorder | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04727502 Comparator | Dec 2020 → Mar 2021 | — | National Cancer Institute, Egypt | Unknown | No outcome recorded |
| Phase 2 | NCT04653337 Background | Sep 2020 → Dec 2023 | depressive disorder | Xijing Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04294953 Comparator | Mar 2020 → Mar 2021 | colorectal cancer | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT04224584 Comparator | Jan 2020 → Jul 2021 | osteoarthritis, knee | Kristian Kjær Petersen | Completed | No outcome recorded |
| Phase 2 | NCT03812523 Comparator | Jun 2019 → Feb 2021 | chemotherapy-induced neuropathy | Southeastern Regional Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03321526 Background | Dec 2017 → Jun 2019 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03364075 Comparator | Sep 2017 → May 2018 | — | Mark Ware | Terminated | No outcome recorded |
| Phase 2 | NCT01846182 Comparator | Jun 2015 → Aug 2019 | persian gulf syndrome | VA Office of Research and Development | Terminated | No outcome recorded |
| Phase 2 | NCT01564862 Comparator | Apr 2012 → Feb 2014 | major depressive disorder | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT01579279 Comparator | Apr → May 2012 | diabetic neuropathy | AbbVie | Terminated | No outcome recorded |
| Phase 2 | NCT01369095 Comparator | Jul 2011 → May 2013 | depressive disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01309945 Comparator | Apr 2011 → Jan 2013 | depressive disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01288079 Comparator | Feb 2011 → Aug 2012 | major depressive disorder | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT01145755 Comparator | May → Nov 2010 | major depressive disorder | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT00940693 Comparator | Aug 2009 → Dec 2010 | attention deficit-hyperactivity disorder | University of Montreal | Completed | No outcome recorded |
| Phase 2 | NCT00854100 Background | Jun 2009 → Dec 2010 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 2 | NCT00603265 Comparator | Nov 2007 → Aug 2008 | neuropathy, painful, peripheral neuropathy | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00599911 Comparator | Oct 2007 → Mar 2009 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 2 | NCT00507936 Comparator | Aug 2007 → Oct 2008 | diabetic polyneuropathy, neuropathy, painful | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT00331799 Comparator | Apr 2007 → May 2008 | major depressive disorder | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT01223001 Comparator | Sep 1996 → Jul 2011 | depressive disorder, traumatic brain injury | Rehabilitation Hospital of Indiana | Terminated | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05786599 Comparator | Mar 2025 → Mar 2026 overdue | chemotherapy-induced neuropathy | University of British Columbia | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03487211 Comparator | Apr 2018 → Feb 2020 | fibromyalgia | Shaheed Zulfiqar Ali Bhutto Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT03037073 Comparator | Apr 2017 → Nov 2019 | — | Assiut University | Completed | No outcome recorded |
| Phase 331 trials | ||||||
| Phase 3 | NCT07296770 Background | Oct 2026 → Dec 2027 expected | chronic pain syndrome | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06715462 Comparator | Apr 2026 → Mar 2028 | diabetic polyneuropathy | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT06860984 Comparator | Mar 2025 → Jun 2026 overdue | biliary tract disorder | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT07253207 Comparator | Oct 2024 → Jun 2025 | major depressive disorder | Zhejiang Huahai Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05840562 Comparator | Oct 2023 → Mar 2028 expected | chemotherapy-induced neuropathy | Institut Cancerologie de l'Ouest | Recruiting | No outcome recorded |
| Phase 3 | NCT06025474 Comparator | Jan → Oct 2023 | burning mouth syndrome | Federico II University | Unknown | No outcome recorded |
| Phase 3 | NCT04504812 Comparator | Feb 2021 → Apr 2025 | osteoarthritis, knee | Johns Hopkins University | Completed | No outcome recorded |
| Phase 3 | NCT04476030 Background | Nov 2020 → Oct 2021 | major depressive disorder | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT03852160 Background | Dec 2019 → Jul 2021 | major depressive disorder | Janssen-Cilag International NV | Withdrawn | No outcome recorded |
| Phase 3 | NCT03538691 Background | Jul 2018 → Jul 2022 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03434041 Background | May 2018 → Apr 2021 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02493868 Background | Oct 2015 → Feb 2018 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02497287 Background | Sep 2015 → Oct 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02422186 Background | Aug 2015 → Aug 2017 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02417064 Background | Aug 2015 → Feb 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02418585 Background | Aug 2015 → Jun 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02443194 Comparator | May → Nov 2015 | depressive disorder | michal roll | Terminated | No outcome recorded |
| Phase 3 | NCT02367404 Comparator | May 2015 → Feb 2017 | prostate cancer | Institut Mutualiste Montsouris | Unknown | No outcome recorded |
| Phase 3 | NCT02400346 Background | Mar 2015 → Jun 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT01838681 Background | Jun 2013 → Jun 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT01838876 Background | Apr 2013 → Jul 2015 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01715805 Background | Nov 2012 → Jun 2016 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01436175 Background | Feb 2012 → Mar 2014 | major depressive disorder | Shire | Terminated | No outcome recorded |
| Phase 3 | NCT01436162 Background | Oct 2011 → Dec 2013 | major depressive disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT01360866 Background | Oct 2011 → Apr 2017 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01153009 Comparator | Jun 2010 → Mar 2012 | major depressive disorder | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00730691 Comparator | Jun 2008 → Feb 2009 | generalized anxiety disorder | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00672620 Comparator | Apr → Nov 2008 | major depressive disorder | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00471315 Comparator | Jul 2006 → Mar 2012 | biliary dyskinesia | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 3 | NCT00351910 Background | May 2006 → Apr 2007 | major depressive disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00114127 Comparator | Jun 2004 → Nov 2008 | anxiety disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 429 trials | ||||||
| Phase 4 | NCT06968624 Background | Jun 2025 → Apr 2026 overdue | depressive disorder, postherpetic neuralgia | Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07439536 Comparator | Jul 2024 → Jul 2025 | cirrhosis of liver | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT06245109 Comparator | Feb 2024 → Mar 2028 expected | osteoarthritis, knee | Northwestern University | Recruiting | No outcome recorded |
| Phase 4 | NCT05396014 Comparator | Sep 2022 → Jul 2024 | chronic pain syndrome | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT05050656 Comparator | Mar → Jul 2021 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT05296759 Comparator | Feb → Nov 2021 | diabetic neuropathy | Alexandria University | Completed | No outcome recorded |
| Phase 4 | NCT06837012 Comparator | Jan 2021 → Jul 2022 | osteoarthritis, knee | Orthopaedic Arthroscopy Knee and Shoulder Clinic | Completed | No outcome recorded |
| Phase 4 | NCT04245748 Comparator | Mar 2020 → Jul 2025 overdue | mixed anxiety and depressive disorder | University of Cincinnati | Recruiting | No outcome recorded |
| Phase 4 | NCT04245436 Comparator | Jan 2020 → Jul 2025 overdue | anxiety, depressive disorder | University of Cincinnati | Recruiting | No outcome recorded |
| Phase 4 | NCT03618225 Comparator | Aug 2018 → Jan 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT03321006 Comparator | May 2018 → May 2021 | depressive disorder, hearing loss disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT03249558 Comparator | Mar 2018 → Apr 2022 | chronic pain syndrome | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03249311 Comparator | Mar 2018 → Dec 2019 | — | University of Ottawa | Unknown | No outcome recorded |
| Phase 4 | NCT04532684 Comparator | Oct 2016 → Jul 2020 | osteoarthritis, knee | Fatih Sultan Mehmet Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02670161 Comparator | May 2016 → Dec 2026 expected | Parkinson disease, brain neoplasm, cognitive impairment with or without cerebellar ataxia, epilepsy +6 | Endeavor Health | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT03250494 Comparator | Dec 2014 → Jan 2016 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02535000 Comparator | Jan 2014 → Oct 2015 | intervertebral disk degenerative disorder | Serviço de Anestesiologia de Joinville | Completed | No outcome recorded |
| Phase 4 | NCT02612233 Comparator | Sep 2013 → May 2016 | osteoarthritis, hand | St George's, University of London | Completed | No outcome recorded |
| Phase 4 | NCT01764867 Comparator | Jun 2012 → Oct 2014 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT01443520 Comparator | Oct 2011 → Jan 2012 | — | Turku University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01451606 Comparator | Jul 2011 → Nov 2015 | chronic pain syndrome | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 4 | NCT01116531 Comparator | Apr 2010 → Dec 2012 | diabetic polyneuropathy, postherpetic neuralgia | Turku University Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT01077375 Comparator | Feb → Dec 2010 | fibromyalgia | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT01305707 Comparator | Jul 2009 → Jul 2014 | major depressive disorder | Hospital Universitari de Bellvitge | Terminated | No outcome recorded |
| Phase 4 | NCT00619983 Comparator | Feb 2008 → May 2013 | chronic pain syndrome, diabetic neuropathy | Wake Forest University | Terminated | No outcome recorded |
| Phase 4 | NCT01148472 Comparator | Sep 2005 → Sep 2006 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 4 | NCT00200902 Comparator | Aug 2005 → Jun 2009 | depressive disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT00494377 Background | Feb 2004 → Jun 2005 | depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00177671 Background | Dec 2003 → Sep 2009 | dementia, major depressive disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase not applicable39 trials | ||||||
| — | NCT07645482 Comparator | Jul → Aug 2026 overdue | diabetic polyneuropathy | Beni-Suef University | Not yet recruiting | No outcome recorded |
| — | NCT07455838 Background | Mar → May 2026 overdue | female stress incontinence | Cairo University | Not yet recruiting | No outcome recorded |
| — | NCT07203339 Comparator | Sep 2025 → Dec 2028 expected | fibromyalgia | Hospital de Clinicas de Porto Alegre | Recruiting | No outcome recorded |
| — | NCT07025590 Comparator | Apr 2025 → Dec 2026 expected | cardiovascular disorder, mixed anxiety and depressive disorder | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| — | NCT06896994 Background | Apr 2025 → Apr 2026 overdue | postherpetic neuralgia | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT06301061 Comparator | Apr 2024 → Oct 2025 | chronic pain syndrome, neuropathy, painful, radiculopathy | Federico II University | Unknown | No outcome recorded |
| — | NCT07593313 Background | Jan 2024 → Aug 2026 overdue | — | Nanchong Central Hospital | Recruiting | No outcome recorded |
| — | NCT06087211 Comparator | Oct 2023 → Jan 2025 | myofascial pain syndrome | National Cancer Institute, Egypt | Completed | No outcome recorded |
| — | NCT06237595 Comparator | Sep 2023 → Oct 2024 | fibromyalgia | Kasr El Aini Hospital | Unknown | No outcome recorded |
| — | NCT05560516 Comparator | Dec 2022 → Dec 2024 | chemotherapy-induced neuropathy | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| — | NCT07533487 Background | Sep 2022 → Jan 2025 | fibromyalgia | Cairo University | Completed | No outcome recorded |
| — | NCT05254652 Background | May 2022 → May 2023 | osteoarthritis | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT05256342 Comparator | Dec 2021 → Apr 2024 | osteoarthritis, knee | Rambam Health Care Campus | Completed | No outcome recorded |
| — | NCT04847245 Comparator | May 2021 → Dec 2022 | chronic pain syndrome, major depressive disorder | Peking University | Unknown | No outcome recorded |
| — | NCT05937711 Background | Nov 2020 → May 2022 | fibromyalgia | Ilker Fatih Sari | Completed | No outcome recorded |
| — | NCT04316702 Comparator | Mar 2020 → Nov 2023 | fibromyalgia | Assaf-Harofeh Medical Center | Completed | No outcome recorded |
| — | NCT05558397 Comparator | Apr 2018 → Dec 2022 | — | Federal University of Alfenas | Completed | No outcome recorded |
| — | NCT03468348 Comparator | Apr 2018 → Feb 2020 | — | Assiut University | Completed | No outcome recorded |
| — | NCT03350334 Comparator | Dec 2017 → Mar 2018 | — | Acibadem University | Completed | No outcome recorded |
| — | NCT03325959 Comparator | Mar 2017 → Jun 2022 | fibromyalgia | Assaf-Harofeh Medical Center | Completed | No outcome recorded |
| — | NCT02672202 Comparator | Feb 2016 → May 2017 | chronic pain syndrome | Rambam Health Care Campus | Terminated | No outcome recorded |
| — | NCT02655354 Background | Oct 2015 → Nov 2019 | alcohol-related disorders, brain injury, cognitive impairment with or without cerebellar ataxia, depressive disorder +1 | University of Washington | Completed | No outcome recorded |
| — | NCT02020122 Comparator | Jan 2014 → Jan 2015 | — | Rambam Health Care Campus | Completed | No outcome recorded |
| — | NCT01943435 Comparator | Nov 2013 → Jun 2016 | lumbar spinal stenosis | Michael Schneider, DC, PhD | Completed | No outcome recorded |
| — | NCT01944657 Comparator | Sep 2013 → Dec 2015 | major depressive disorder | Sheppard Pratt Health System | Withdrawn | No outcome recorded |
| — | NCT01896349 Background | Apr 2013 → Aug 2014 | — | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| — | NCT01470339 Comparator | Dec 2011 → Jul 2014 | — | Rambam Health Care Campus | Completed | No outcome recorded |
| — | NCT01470352 Comparator | Nov 2011 → Nov 2017 | migraine disorder | d_yarnitsky | Completed | No outcome recorded |
| — | NCT01488266 Comparator | Nov 2011 → Jan 2013 | major depressive disorder | Korea University | Unknown | No outcome recorded |
| — | NCT02903238 Background | Jul → Oct 2011 | osteoarthritis, knee | Northwestern University | Completed | No outcome recorded |
| — | NCT01268631 Comparator | Jan 2011 → Jan 2013 | fibromyalgia | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT01404871 Comparator | Apr 2009 → Oct 2011 | obsessive-compulsive disorder | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| — | NCT00596986 Comparator | Oct 2008 → Sep 2009 | dysthymic disorder | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| — | NCT01359514 Comparator | Apr 2008 → Jan 2014 | — | Rambam Health Care Campus | Completed | No outcome recorded |
| — | NCT00564278 Background | Feb 2008 → Aug 2013 | depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| — | NCT00660751 Comparator | Aug 2007 → Apr 2012 | — | Rambam Health Care Campus | Completed | No outcome recorded |
| — | NCT00360399 Comparator | Aug 2006 → Apr 2015 | major depressive disorder | Emory University | Completed | No outcome recorded |
| — | NCT00817011 Comparator | Apr 2006 → Dec 2016 | depressive disorder | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT00149110 Comparator | Sep 2005 → Mar 2009 | major depressive disorder | Hillerod Hospital, Denmark | Completed | No outcome recorded |
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 390 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | duloxetine | “we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These...” NCT02458690 ↗377“Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ “ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its...” NCT01838876 ↗ “Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine,...” NCT02400346 ↗ “Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week...” NCT00854100 ↗ “SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine...” NCT01436175 ↗ “This study will determine the influence of methylphenidate (e.g., Ritalin®) and duloxetine (Cymbalta®), alone and in combination, on the cocaine use as measured by self-report...” NCT02700711 ↗ “If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will...” NCT04478526 ↗ “Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.” NCT00742573 ↗ “quantifying the range of concentration to citalopram, escitalopram, sertraline, fluoxetine, paroxetine, fluvoxamine, duloxetine and venlafaxine in mother plasma and breast milk” NCT01796132 ↗ “The drugs included in the treatment plan are morphine (60 mg/day), pregabalin (150 mg/day) and duloxetine (60 mg/day), available free of charge to the participating patients.” NCT05558397 ↗ “We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight.” NCT04437485 ↗ “ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.” NCT01715805 ↗ “Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily” NCT01436162 ↗ “Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy” NCT03321526 ↗ “If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.” NCT01973283 ↗ “Duloxetine ("Cymbalta") is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy.” NCT03271151 ↗ “Duloxetine which is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases urethral sphincter tone will be used for both groups.” NCT07455838 ↗ “Patients who at 4 weeks of escitalopram have not responded will be shifted to duloxetine at flexible standard dosages.” NCT02869035 ↗ “Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.” NCT01077375 ↗ “In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine” NCT02711215 ↗ “If the participant cannot tolerate or has an adverse reaction to escitalopram, duloxetine will be offered instead.” NCT04836533 ↗ “Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label” NCT01838681 ↗ “pain relievers such as acetaminophen and antidepressants such as Duloxetine (Cymbalta) and milnacipran” NCT07533487 ↗ “Adjunctive antidepressant agents: nortriptyline, duloxetine, sertraline, trazodone, or mirtazapine” NCT01943435 ↗ “Dulsevia® (duloxetine) hard gastro-resistant capsules of different strenghts: 30 mg and 60 mg.” NCT04246619 ↗ “AD: aripiprazole, bupropion, duloxetine, escitalopram, mirtazapine, sertraline, venlafaxine” NCT04747314 ↗ “Gabapentin 300 mg capsule once at night, and Duloxetine 30 mg cap once daily for 30 days.” NCT06237595 ↗ “Sertraline 50 mg/day or Duloxetine 60 mg/day or Bupropion XL 150-300 mg/day” NCT07654179 ↗ “Cymbalta® (duloxetine hydrochloride 60 mg, delayed-release capsule)” NCT06715462 ↗ “Duloxetine will be given in a daily dose of 30 mg for 5 weeks” NCT01470352 ↗ “Duloxetine and Dexamethasone for Improving Postoperative Pain” NCT03250494 ↗ “receiving the combination of pregabalin and duloxetine” NCT06896994 ↗ “neuropathy (duloxetine, pregabalin, amitryptiline)” NCT02670161 ↗ “duloxetine (Cymbalta®) delayed-release capsules” NCT03538691 ↗ “Duloxetine hydrochloride enteric coated capsule” NCT06259526 ↗ “combined with SNRIs（Venlafaxine or Duloxetine）” NCT04653337 ↗ “duloxetine (60 mg, increased to 120 mg)” NCT00118430 ↗ “- Duloxetine 60-120 mg/d. N06AX21” NCT01305707 ↗ “duloxetine_Cymbalta, Yentreve” NCT00817011 ↗ “Duloxetine Hydrochloride” NCT07296770 ↗ “duloxetine (Cymbalta)” NCT01944657 ↗ “Duloxetine, Cymbalta” NCT01916824 ↗ “duloxetine 60mg” NCT02020122 ↗ “duloxetine” NCT01488266 ↗ |
| Known as | Ariclaim | ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗ |
| Known as | Cymbalta | “Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗23“Experimental: Duloxetine group 1. Phase I (preemptive): 1day before operation (30mg for 1 day) 2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus...” NCT02600247 ↗ “Duloxetine(Cymbalta) for Fibromyalgia: An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic...” NCT01127490 ↗ “The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients...” NCT00185575 ↗ “Duloxetine ("Cymbalta") is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy.” NCT03271151 ↗ “Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.” NCT03729284 ↗ “35 patients will receive duloxetine (Cymbalta; Eli Lilly \& Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.” NCT03037073 ↗ “Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.” NCT03794154 ↗ “Duloxetine (Cymbalta) is one of the newer antidepressants approved for the treatment of Major Depressive Disorder (MDD).” NCT00517985 ↗ “pain relievers such as acetaminophen and antidepressants such as Duloxetine (Cymbalta) and milnacipran” NCT07533487 ↗ “impact of duloxetine ("Cymbalta"), a serotonin and norepinephrine reuptake inhibitor” NCT02005601 ↗ “The initial dose of duloxetine (Cymbalta, Eli Lilly, USA) will be 30mg once daily.” NCT01116531 ↗ “Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)” NCT00200902 ↗ “Cymbalta® (duloxetine hydrochloride 60 mg, delayed-release capsule)” NCT06715462 ↗ “The drug, Duloxetine, is marketed under the trade name Cymbalta.” NCT01451606 ↗ “Cymbalta® 60 mg capsule of Eli Lilly and Company” NCT02291341 ↗ “duloxetine (Cymbalta®) delayed-release capsules” NCT03538691 ↗ “duloxetine_Cymbalta, Yentreve” NCT00817011 ↗ “duloxetine (Cymbalta)” NCT01944657 ↗ |
| Known as | Cymbalta (duloxetine) | “Cymbalta (duloxetine)” NCT00889369 ↗ |
| Known as | Cymbatex | “one capsule of Duloxetine 30 mg (Cymbatex 30 mg, EVA Pharma)” NCT07421427 ↗ |
| Known as | DLX | “Duloxetine (DLX)” NCT00945945 ↗ |
| Known as | Drizalma sprinkle | ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗ |
| Known as | Duciltia | ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗ |
| Known as | DUL | “45 patients will be assigned into each group, by order of their recruitment. Third of the patients in each group will be randomized to Duloxetine (DUL), third to Pregabalin...” NCT02672202 ↗ |
| Known as | Duloxetina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗ |
| Known as | Duloxetine (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗ |
| Known as | Duloxetine boehringer ingelheim | ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗ |
| Known as | Duloxetine HCl | “In the duloxetine group, one capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation.” NCT03792828 ↗1“Totally, 144 received 60 mg/day of duloxetine HCL and 144 received placebo for 16 weeks.” PMID 22743149 ↗ Jun 2012 |
| Known as | duloxetine hydrochloride | “To determine the dosage of duloxetine hydrochloride (duloxetine) (30 mg or 60 mg daily) that appears most promising in preventing oxaliplatin-induced peripheral neuropathy (OIPN).” NCT04137107 ↗18“Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.” NCT03729284 ↗ “Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.” NCT03794154 ↗ “Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.” NCT04364997 ↗ “Duloxetine Hydrochloride (LY248686) Protocol F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain” NCT00036335 ↗ “Generic Duloxetine Hydrochloride (Germed) will be purchased and sent for fractioning and placebo preparation.” NCT07203339 ↗ “Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.” NCT05508516 ↗ “Cymbalta® (duloxetine hydrochloride 60 mg, delayed-release capsule)” NCT06715462 ↗ “Drug: Duloxetine Hydrochloride” NCT03110172 ↗ “Drug: Duloxetine hydrochloride” NCT00422162 ↗ “Drug: Duloxetine hydrochloride” NCT00536471 ↗ “Drug: duloxetine hydrochloride” NCT00673452 ↗ “Drug: duloxetine hydrochloride” NCT00385671 ↗ “Drug: Duloxetine hydrochloride” NCT00583193 ↗ |
| Known as | Duloxetine Hydrochloride Enteric Capsules | “Duloxetine Hydrochloride Enteric Capsules 60mg/day is to be given orally, once daily, for 8 weeks.” NCT07253207 ↗ |
| Known as | Duloxetine hydrochloride enteric-coated capsules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05018013 ↗ |
| Known as | Duloxetine lilly | ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗ |
| Known as | Duloxetine mylan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗ |
| Known as | Duloxetine zentiva | ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗ |
| Known as | Duloxetine, Cymbalta | “Duloxetine, Cymbalta” NCT01916824 ↗ |
| Known as | Dulsevia | “Dulsevia® (duloxetine) hard gastro-resistant capsules of different strenghts: 30 mg and 60 mg.” NCT04246619 ↗ |
| Known as | Duroceptol | “In the duloxetine group, one capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation.” NCT03792828 ↗ |
| Known as | LY-248686 HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗ |
| Known as | LY248686 | “Duloxetine Hydrochloride (LY248686) Protocol F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain” NCT00036335 ↗ |
| Known as | Nodetrip (previously xeristar) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗ |
| Known as | NSC-759112 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗ |
| Known as | Xeristar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1175 ↗ |
| Known as | Yentreve | “duloxetine_Cymbalta, Yentreve” NCT00817011 ↗ |
| Action | Inhibit | “The purpose of this non-inferiority study was to compare the speed of onset of antidepressant efficacy for duloxetine (a dual serotonin and norepinephrine reuptake inhibitor)...” PMID 17288694 ↗ Feb 2007 |
| Modality | Small molecule | “Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI)” NCT00438971 ↗ |
| Route | Oral | “duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks” NCT00105989 ↗ |
| Target | CYP2D6 | “Duloxetine is known to inhibit CYP2D6.” NCT01443520 ↗ |
| Target | SLC6A2 | “Norepinephrine transporter inhibitor” CHEMBL1175 ↗ |
| Target | SLC6A4 | “Serotonin transporter inhibitor” CHEMBL1175 ↗ |